Metastatic hormone-resistant prostate cancer is prostate cancer that has spread to other parts of the body and continues to grow despite very low testosterone levels. Although several treatments are available, many men eventually need additional treatment options. Researchers continue to study new therapies that may help control the disease and improve quality of life. Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for...

Metastatic hormone-resistant prostate cancer is prostate cancer that has spread to other parts of the body and continues to grow despite treatments that keep testosterone levels very low. Although treatment options are available, many men eventually need additional therapies. Researchers continue to study new approaches that may help slow disease progression, improve quality of life, and provide additional treatment options. Official Title: A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus...